logo
Trump administration asks Supreme Court to allow NIH to cancel health grants

Trump administration asks Supreme Court to allow NIH to cancel health grants

The Hill24-07-2025
The Trump administration asked the Supreme Court on Thursday to allow it to continue moving forward with canceling National Institutes of Health (NIH) grants over their connections to diversity initiatives.
The Department of Justice (DOJ) asked the court for an emergency stay that would stop Boston-based U.S. District Judge William Young's ruling last month, which halted the cancellation and forced the government to reinstate several of the grants.
The case centered on a legal challenge by researchers, unions and a coalition of 16 Democratic-led states. They sued the administration after the NIH terminated grants supporting research on topics like health equity, racial disparities, vaccine hesitancy and maternal health in minority communities.
The abrupt cancellations were part of the administration's quest to slash spending and end federal support for initiatives Trump officials considered to be promoting diversity, equity and inclusion (DEI).
'The district court's order directs the NIH to continue paying $783 million in federal grants that are undisputedly counter to the Administration's priorities,' DOJ wrote in the filing.
'Following the change in Administration, the NIH identified, explained, and pursued new funding priorities. That is democracy at work, not, as the district court thought, proof of inappropriate 'partisan[ship]'—let alone a permissible basis for setting agency action aside,' the filing stated.
The Trump administration has repeatedly asked the Supreme Court to step in when its policies have been blocked by lower courts. Thursday's filing was the administration's 21st emergency application since taking office, and the White House has found success in nearly every single instance.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Supreme Court just dropped a hint about its next big Voting Rights Act case
The Supreme Court just dropped a hint about its next big Voting Rights Act case

Politico

time9 minutes ago

  • Politico

The Supreme Court just dropped a hint about its next big Voting Rights Act case

The order came in a case challenging Louisiana's congressional map, which contains two majority-Black districts out of the state's six House seats. The court heard arguments in the case in March and had been expected to rule by June. But on June 27, the justices punted the case into their next term and ordered that it be reargued. Now, Friday's order loosely sketches the terrain on which the justices want further arguments: the claim that the longstanding practice of drawing majority-minority districts under the Voting Rights Acts may be unconstitutional because of its focus on race in drawing district lines. The voters challenging Louisiana's map had already advanced that constitutional claim in the case, but the justices' call for further briefing on the issue suggests they want to consider the claim more fully. Section 2 of the Voting Rights Act, a landmark law passed during the civil rights era, generally prohibits race-based discrimination in voting laws and practices. In redistricting, the law is used to protect against racial gerrymandering that would unfairly dilute the voting power of racial and ethnic minority voters. States across the country routinely seek to comply with Section 2 by drawing congressional districts where minority voters can elect their chosen candidates. Louisiana's previous map contained only one majority-Black district, even though Black residents make up about a third of the state's population. After a court struck down that map for likely violating the Voting Rights Act because it diluted the power of Black voters, the state's Republican-controlled legislature drew the new map with two majority-Black districts. A group of voters — who self-identified as non-Black — challenged the new map. That's the case now before the Supreme Court. A ruling overturning the current map could result in Republicans picking up an additional congressional seat in Louisiana. The state's two majority-Black districts are both represented by Democrats, while the other four districts are represented by Republicans.

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say

CBS News

time9 minutes ago

  • CBS News

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say

Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store